Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 5948Pancreatic Neoplasms 3563Carcinoma, Hepatocellular 3273Stomach Neoplasms 3057Colonic Neoplasms 2328Rectal Neoplasms 2192Esophageal Neoplasms 1801Liver Neoplasms 1247Neoplasms 1181Breast Neoplasms 1064Neoplasm Metastasis 871Carcinoma, Non-Small-Cell Lung 794Lung Neoplasms 745Cholangiocarcinoma 743Gastrointestinal Neoplasms 662Ovarian Neoplasms 630Esophageal Squamous Cell Carcinoma 585Prostatic Neoplasms 485Melanoma 457Biliary Tract Neoplasms 441Head and Neck Neoplasms 376Uterine Cervical Neoplasms 344Carcinoma, Renal Cell 329Gastrointestinal Stromal Tumors 326Adenocarcinoma Of Esophagus 315Sarcoma 304Barrett Esophagus 300Anus Neoplasms 284Gallbladder Neoplasms 283Endometrial Neoplasms 281

Interventions

trifluridine tipiracil drug combination 1lenvatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
First-line Treatment × Gastrointestinal × Clear all
NCT05221775 2022-02-03

Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients

Tianjin Medical University Cancer Institute and Hospital

Phase 1 Unknown
18 enrolled
Gastrointestinal

First-line Treatment

NCT05077839 2021-10-25

TOBACO

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
184 enrolled
Gastrointestinal

First-line Treatment

Data powered by HemOnc (CC BY 4.0) Colophon âš¡